Evidence map›Paper›PMID 42000735›Full record

ArticleScientific reports2026

Systematic identification of rare disease patients in electronic health records enables evaluation of clinical outcomes.

Arjun S Yadaw, Eric Sid, Hythem Sidky, Chenjie Zeng, Qian Zhu, Ewy A Mathé, N3C Consortium

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Arjun S YadawDivision of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), NIH, 9800 Medical Center DR-BLDG B, RM 366, Rockville, MD, 20850, USA.
Eric SidDivision of Rare Diseases Research Innovation, Sciences (NCATS), National Center for Advancing Translational, National Institutes of Health, Bethesda, MD, 20892, USA.
Hythem SidkyDivision of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), NIH, 9800 Medical Center DR-BLDG B, RM 366, Rockville, MD, 20850, USA.
Chenjie ZengPrecision Health Informatics Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20814, USA.
Qian ZhuDivision of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), NIH, 9800 Medical Center DR-BLDG B, RM 366, Rockville, MD, 20850, USA.
Ewy A MathéDivision of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), NIH, 9800 Medical Center DR-BLDG B, RM 366, Rockville, MD, 20850, USA. ewy.mathe@nih.gov.
N3C Consortium

Funding

NCATS NIH HHS ZIA ZICTR000410
6 · The paper itself

Abstract

Identifying rare disease (RD) patients in electronic health records (EHRs) is difficult, as most of the over 10,000 RDs are not adequately captured by standard coding systems. To address this, we developed a semi-automated workflow to map RDs to SNOMED-CT and ICD-10 codes, enabling improved RD identification across EHR systems. The optimized workflow yielded 88.4% true RD codes in a subset of 1,715 manually curated diseases. Using this workflow and starting with 12,003 GARD IDs mapped to ORPHANET, we obtained 12,081 SNOMED-CT and 357 ICD-10 codes representing 6,342 RDs, organized into 30 ORPHANET linearization classes. We applied these codes to the National COVID Cohort Collaborative (N3C) dataset of over 21 million patients. Among these patients, 8.46 million were identified as COVID-19 positive, of which 4.8 million were used in analyses. Among these, 316,836 (6.55%) had a preexisting RD. Logistic regression, adjusted for age and BMI, revealed that most RD classes were significantly associated with increased odds of severe COVID-19 outcomes. Notably high odds of mortality were observed for rare cardiac (OR = 4.07) and otorhinolaryngologic diseases (OR = 4.00). Hospitalization risk was also elevated across all RD classes, with the highest odds seen in otorhinolaryngologic (OR = 4.31) and endocrine diseases (OR = 3.38). This approach enables scalable RD patient identification in EHRs and highlights the need for tailored healthcare strategies to improve outcomes in RD populations.

Indexed as

Electronic Health RecordsRare DiseasesCOVID-19HumansInternational Classification of DiseasesSARS-CoV-2Systematized Nomenclature of MedicineWorkflowCOVID-19 outcomesICD-10N3CRare diseaseRare diseases mappingsRetrospective analysisSNOMED-CT

Identifiers

PMID42000735
PMCPMC13276054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.